Cargando…

A cerebrospinal fluid microRNA analysis: Progressive supranuclear palsy

Progressive supranuclear palsy (PSP) is a neurodegenerative tauopathy described as a syndrome of postural instability, supranuclear vertical gaze palsy, dysarthria, dystonic rigidity of the neck and trunk, dementia, and pseudobulbar palsy. The clinical diagnosis of PSP is often difficult because the...

Descripción completa

Detalles Bibliográficos
Autores principales: Nonaka, Wakako, Takata, Tadayuki, Iwama, Hisakazu, Komatsubara, Satoshi, Kobara, Hideki, Kamada, Masaki, Deguchi, Kazushi, Touge, Tetsuo, Miyamoto, Osamu, Nakamura, Takehiro, Itano, Toshifumi, Masaki, Tsutomu
Formato: Online Artículo Texto
Lenguaje:English
Publicado: D.A. Spandidos 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8809115/
https://www.ncbi.nlm.nih.gov/pubmed/35039873
http://dx.doi.org/10.3892/mmr.2022.12604
_version_ 1784643951507013632
author Nonaka, Wakako
Takata, Tadayuki
Iwama, Hisakazu
Komatsubara, Satoshi
Kobara, Hideki
Kamada, Masaki
Deguchi, Kazushi
Touge, Tetsuo
Miyamoto, Osamu
Nakamura, Takehiro
Itano, Toshifumi
Masaki, Tsutomu
author_facet Nonaka, Wakako
Takata, Tadayuki
Iwama, Hisakazu
Komatsubara, Satoshi
Kobara, Hideki
Kamada, Masaki
Deguchi, Kazushi
Touge, Tetsuo
Miyamoto, Osamu
Nakamura, Takehiro
Itano, Toshifumi
Masaki, Tsutomu
author_sort Nonaka, Wakako
collection PubMed
description Progressive supranuclear palsy (PSP) is a neurodegenerative tauopathy described as a syndrome of postural instability, supranuclear vertical gaze palsy, dysarthria, dystonic rigidity of the neck and trunk, dementia, and pseudobulbar palsy. The clinical diagnosis of PSP is often difficult because there are no established biomarkers, and diagnosis is currently based on clinical and imaging findings. Furthermore, the etiology and pathogenesis of PSP remain unknown. Dysregulation of microRNAs (miRNAs/miRs) has been reported to serve an important role in neurodegenerative diseases. However, the miRNA profiles of patients with PSP are rarely reported. The present study aimed to examine cerebrospinal fluid miRNAs, which are considered to be more sensitive indicators of changes in the brain, to elucidate the pathophysiology of PSP and to establish specific biomarkers for diagnosis. The present study used a microarray chip containing 2,632 miRNAs to examine cerebrospinal fluid miRNA expression levels in 11 patients with PSP aged 68–82 years. A total of 8 age- and sex-matched controls were also included. A total of 38 miRNAs were significantly upregulated and one miRNA was significantly downregulated in the cerebrospinal fluid of patients with PSP. The patients were divided into two groups based on disease stage (early onset and advanced), and changes in miRNA expression were examined. The miRNAs that were most significantly upregulated or downregulated in the early onset group were miR-204-3p, miR-873-3p and miR-6840-5p. The target genes of these miRNAs were associated with molecules related to the ubiquitin-proteasome system and autophagy pathway. Furthermore, these miRNAs were found to target genes that have been reported to have epigenetic changes following an epigenome-wide association study of brain tissues of patients with PSP. This suggested that these miRNAs and genes may have some involvement in the pathogenesis of PSP. However, the sample size of the present study was small; therefore, a greater number of patients with PSP should be examined in future studies.
format Online
Article
Text
id pubmed-8809115
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher D.A. Spandidos
record_format MEDLINE/PubMed
spelling pubmed-88091152022-02-03 A cerebrospinal fluid microRNA analysis: Progressive supranuclear palsy Nonaka, Wakako Takata, Tadayuki Iwama, Hisakazu Komatsubara, Satoshi Kobara, Hideki Kamada, Masaki Deguchi, Kazushi Touge, Tetsuo Miyamoto, Osamu Nakamura, Takehiro Itano, Toshifumi Masaki, Tsutomu Mol Med Rep Articles Progressive supranuclear palsy (PSP) is a neurodegenerative tauopathy described as a syndrome of postural instability, supranuclear vertical gaze palsy, dysarthria, dystonic rigidity of the neck and trunk, dementia, and pseudobulbar palsy. The clinical diagnosis of PSP is often difficult because there are no established biomarkers, and diagnosis is currently based on clinical and imaging findings. Furthermore, the etiology and pathogenesis of PSP remain unknown. Dysregulation of microRNAs (miRNAs/miRs) has been reported to serve an important role in neurodegenerative diseases. However, the miRNA profiles of patients with PSP are rarely reported. The present study aimed to examine cerebrospinal fluid miRNAs, which are considered to be more sensitive indicators of changes in the brain, to elucidate the pathophysiology of PSP and to establish specific biomarkers for diagnosis. The present study used a microarray chip containing 2,632 miRNAs to examine cerebrospinal fluid miRNA expression levels in 11 patients with PSP aged 68–82 years. A total of 8 age- and sex-matched controls were also included. A total of 38 miRNAs were significantly upregulated and one miRNA was significantly downregulated in the cerebrospinal fluid of patients with PSP. The patients were divided into two groups based on disease stage (early onset and advanced), and changes in miRNA expression were examined. The miRNAs that were most significantly upregulated or downregulated in the early onset group were miR-204-3p, miR-873-3p and miR-6840-5p. The target genes of these miRNAs were associated with molecules related to the ubiquitin-proteasome system and autophagy pathway. Furthermore, these miRNAs were found to target genes that have been reported to have epigenetic changes following an epigenome-wide association study of brain tissues of patients with PSP. This suggested that these miRNAs and genes may have some involvement in the pathogenesis of PSP. However, the sample size of the present study was small; therefore, a greater number of patients with PSP should be examined in future studies. D.A. Spandidos 2022-03 2022-01-14 /pmc/articles/PMC8809115/ /pubmed/35039873 http://dx.doi.org/10.3892/mmr.2022.12604 Text en Copyright: © Nonaka et al. https://creativecommons.org/licenses/by-nc-nd/4.0/This is an open access article distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivs License (https://creativecommons.org/licenses/by-nc-nd/4.0/) , which permits use and distribution in any medium, provided the original work is properly cited, the use is non-commercial and no modifications or adaptations are made.
spellingShingle Articles
Nonaka, Wakako
Takata, Tadayuki
Iwama, Hisakazu
Komatsubara, Satoshi
Kobara, Hideki
Kamada, Masaki
Deguchi, Kazushi
Touge, Tetsuo
Miyamoto, Osamu
Nakamura, Takehiro
Itano, Toshifumi
Masaki, Tsutomu
A cerebrospinal fluid microRNA analysis: Progressive supranuclear palsy
title A cerebrospinal fluid microRNA analysis: Progressive supranuclear palsy
title_full A cerebrospinal fluid microRNA analysis: Progressive supranuclear palsy
title_fullStr A cerebrospinal fluid microRNA analysis: Progressive supranuclear palsy
title_full_unstemmed A cerebrospinal fluid microRNA analysis: Progressive supranuclear palsy
title_short A cerebrospinal fluid microRNA analysis: Progressive supranuclear palsy
title_sort cerebrospinal fluid microrna analysis: progressive supranuclear palsy
topic Articles
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8809115/
https://www.ncbi.nlm.nih.gov/pubmed/35039873
http://dx.doi.org/10.3892/mmr.2022.12604
work_keys_str_mv AT nonakawakako acerebrospinalfluidmicrornaanalysisprogressivesupranuclearpalsy
AT takatatadayuki acerebrospinalfluidmicrornaanalysisprogressivesupranuclearpalsy
AT iwamahisakazu acerebrospinalfluidmicrornaanalysisprogressivesupranuclearpalsy
AT komatsubarasatoshi acerebrospinalfluidmicrornaanalysisprogressivesupranuclearpalsy
AT kobarahideki acerebrospinalfluidmicrornaanalysisprogressivesupranuclearpalsy
AT kamadamasaki acerebrospinalfluidmicrornaanalysisprogressivesupranuclearpalsy
AT deguchikazushi acerebrospinalfluidmicrornaanalysisprogressivesupranuclearpalsy
AT tougetetsuo acerebrospinalfluidmicrornaanalysisprogressivesupranuclearpalsy
AT miyamotoosamu acerebrospinalfluidmicrornaanalysisprogressivesupranuclearpalsy
AT nakamuratakehiro acerebrospinalfluidmicrornaanalysisprogressivesupranuclearpalsy
AT itanotoshifumi acerebrospinalfluidmicrornaanalysisprogressivesupranuclearpalsy
AT masakitsutomu acerebrospinalfluidmicrornaanalysisprogressivesupranuclearpalsy
AT nonakawakako cerebrospinalfluidmicrornaanalysisprogressivesupranuclearpalsy
AT takatatadayuki cerebrospinalfluidmicrornaanalysisprogressivesupranuclearpalsy
AT iwamahisakazu cerebrospinalfluidmicrornaanalysisprogressivesupranuclearpalsy
AT komatsubarasatoshi cerebrospinalfluidmicrornaanalysisprogressivesupranuclearpalsy
AT kobarahideki cerebrospinalfluidmicrornaanalysisprogressivesupranuclearpalsy
AT kamadamasaki cerebrospinalfluidmicrornaanalysisprogressivesupranuclearpalsy
AT deguchikazushi cerebrospinalfluidmicrornaanalysisprogressivesupranuclearpalsy
AT tougetetsuo cerebrospinalfluidmicrornaanalysisprogressivesupranuclearpalsy
AT miyamotoosamu cerebrospinalfluidmicrornaanalysisprogressivesupranuclearpalsy
AT nakamuratakehiro cerebrospinalfluidmicrornaanalysisprogressivesupranuclearpalsy
AT itanotoshifumi cerebrospinalfluidmicrornaanalysisprogressivesupranuclearpalsy
AT masakitsutomu cerebrospinalfluidmicrornaanalysisprogressivesupranuclearpalsy